Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine plus myeloablative total body irradiation before allogeneic HCT in AML
2019-004010-34Phase 2Terminated
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Relapse-free survival. Started Nov 2019; status: terminated.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-004010-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004010-34.